|
XENE | Xenon Pharmaceuticals Inc. |
|
|
XENE | Xenon Pharmaceuticals Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.17 |
| Leverage | 7.95% |
| Market Cap | $ 3.2B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -305.3m |
| Margin | -792.25% |
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders in Canada. The company is headquartered in Burnaby, Canada.